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crobiota transplantation (FMT), which has revealed 
promising results in some  [1, 2] but not all  [3] of the first 
high-quality trials in ulcerative colitis, whereas the cur-
rently available evidence in Crohn’s disease  [4] has to be 
considered insufficient. FMT represents a rather drastic 
microbiota-modulating-approach, where the jury – de-
spite an increase in reassuring real-life data from several 
hundreds if not thousands on ultimate long-term safety – 
still has to consider this approach. While first initiatives 
on shaping the future on “Next-Generation Microbiota 
Therapeutics” emerge  [5] , one might forget that we al-
ready have a large armamentarium of established, safe, 
effective, low-priced and generally available microbiota-
modulating agents of variable specificity in our hands – 
antibiotics.
 The available evidence on the efficacy in IBD is con-
siderably limited and the number of included patients in 
high-quality double-blind randomized trials is small  [6] . 
This may be one reason why their general role in the treat-
ment of both Crohn’s disease (aside from penetrating 
complications or prophylaxis of postoperative recur-
rence) and ulcerative colitis (aside from pouchitis) is neg-
ligible, which is also reflected in established treatment 
guidelines  [7, 8] . The paucity of available data is even 
more of an issue in very-early onset IBD. And this is the 
case, even if it appears plausible to assume that aside from 
genetic factors, the contribution of intestinal dysbiosis – 
which may be a direct consequence of a distinct gene-
 “Inflammatory bowel disease (IBD) refers to a group 
of chronic inflammatory disease of the gastrointestinal 
tract that is characterized by an inadequate immune re-
sponse, modulated by genetics and environmental factors 
against the commensal intestinal microbiota.” A sentence 
resembling the former represents a frequently used intro-
duction for any scientific paper on IBD to outline the cur-
rent concept of IBD. Indeed, the intestinal microbiota 
nowadays is among the most frequently mentioned 
pathophysiological hallmarks, whenever the current un-
derstanding of disease pathogenesis is discussed. In line 
with this, we are being confronted with an increasing 
number of original publications and review papers on mi-
crobial composition in IBD patients, focusing on altera-
tions as compared to non-IBD subjects.
 Yet, in striking contrast to the increasing amount of 
descriptive literature as well as a general rise in the gen-
eral interest in this topic by both clinical and scientific 
gastroenterologists, there is a paucity of therapeutic ap-
proaches to target the well-established dysbiosis in IBD. 
The vast majority of current and evolving therapeutic tar-
gets address the inadequately stimulated immune re-
sponse aiming at de-activating pro-inflammatory cas-
cades. In relation to the plethora of already available and 
emerging substances, the amount of microbiota-manip-
ulating treatment strategies under development and the 
financial backbone to support such developments are 
rather negligible. Among the few exceptions is fecal mi-
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mediated immune deficiency – fuels the inflammatory 
fire, it may be of utmost importance in the very early on-
set forms of the disease. One potential underlying reason 
for this restriction might be due to the concerns driven by 
a robust body of epidemiological evidence, suggesting an 
increased risk of developing IBD in the future, subse-
quent to infant exposure to antibiotics  [9, 10] , which 
might potentially even be correlated to the number of 
courses of antibiotics received  [11] . Would antibiotics ad-
dressing intestinal dysbiosis in very early onset IBD thus 
represent a “fight-fire-with-fire” approach?
 In this issue of the journal, Lev-Tzion et al.  [12] report 
on their experience with vancomycin and gentamycin to 
treat severe and refractory early onset IBD. In a case series 
of 5 patients with a very early onset of their disease (mean 
age 1.6 years) with refractory disease, a considerable ther-
apeutic success with an agent, dedicated in covering the 
gram-positive spectrum of the intestinal microbiota, 
could be achieved in 4 out of 5 patients. These results were 
obtained with an established antibiotic agent harboring 
and important advantage as opposed to numerous other 
candidate regimens. It has a nearly absent systemic ab-
sorption [13], aside from a limited systemic exposure in 
severely ill patients in the ICU or patients with advanced 
renal failure [14]. 
 Although findings are derived from an uncontrolled 
series with only such a small sample size, they can never 
be considered a basis for advocating a wider clinical ad-
aptation. The work by this Israelian group is important in 
that it may stimulate further research on this topic and 
potentially on other antibiotic agents or even combina-
tions of these in the treatment of IBD, be it in the adult, 
children or even very early-onset population. These at-
tempts might reveal to be even more promising if the pre-
treatment patient’s microbiota composition could be tak-
en into consideration, which might become a realistic op-
tion in view of the increasing dissemination of information 
and falling costs of high-throughput-sequencing ap-
proaches to characterize intestinal microbial composi-
tion. 
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